Literature DB >> 2909160

Isoproterenol induction of vasodepressor-type reaction in vasodepressor-prone persons.

M B Waxman1, L Yao, D A Cameron, R W Wald, J Roseman.   

Abstract

The ability of isoproterenol to induce symptoms and laboratory findings of a vasodepressor reaction was tested in 48 patients, ages 17 to 74, divided into 4 groups according to the reason for their referral. Group 1 comprised 12 patients with vasodepressor syncope, group 2 had 8 patients with syncope of unknown origin, group 3 included 11 patients with syncope due to seizures in 2 and ventricular tachycardia in 9, group 4 had 17 patients with various arrhythmias not associated with syncope. Isoproterenol boluses were administered starting at 2 micrograms and increased in 2-micrograms steps to a maximum of 8 micrograms at 0 degree and +60 degrees. The responses at 0 degrees were all normal. At +60 degrees a vasodepressor reaction consisting of syncope or near syncope, hypotension and bradycardia was produced by isoproterenol (mean dose 6.0 +/- 0.26 micrograms) in 8 patients from group 1 (66.6%), 4 from group 2 (50%), 0 from group 3 and 4 from group 4 (23.5%). Three of the 4 patients in group 4 had a remote history of classic vasodepressor syncope. The overall sensitivity and specificity of the test were 73 and 85%, respectively, while the predictive accuracy of a test with positive or negative outcome were 69 and 89%, respectively. Muscarinic receptor blockade with atropine in 4 patients prevented isoproterenol-induced bradycardia but not hypotension or symptoms of fainting. Beta-adrenergic receptor blockade with propranolol inhibited all aspects of the isoproterenol-induced faint. Thus, the administration of isoproterenol during a passive upright tilt may identify persons who suffer from or are prone to a vasodepressor reaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909160     DOI: 10.1016/0002-9149(89)91076-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Forearm vascular responses during orthostatic stress in control subjects and patients with posturally related syncope.

Authors:  C M Brown; R Hainsworth
Journal:  Clin Auton Res       Date:  2000-04       Impact factor: 4.435

2.  [Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004].

Authors:  K Seidl; A Schuchert; J Tebbenjohanns; W Hartung
Journal:  Z Kardiol       Date:  2005-09

3.  Isoproterenol infusion provokes vasovagal response without upright tilt in a patient exhibiting syncopal episodes.

Authors:  M Shihara; Y Harasawa; S Ando; M Mohri; A Takeshita
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

4.  Head-up tilt table test: how far and how long?

Authors:  R K Khurana; E M Nicholas
Journal:  Clin Auton Res       Date:  1996-12       Impact factor: 4.435

Review 5.  The fainting patient: value of the head-upright tilt-table test in adult patients with orthostatic intolerance.

Authors:  M Lamarre-Cliche; J Cusson
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

6.  Pathogenesis and management of delayed orthostatic hypotension in patients with chronic fatigue syndrome.

Authors:  F De Lorenzo; J Hargreaves; V V Kakkar
Journal:  Clin Auton Res       Date:  1997-08       Impact factor: 4.435

Review 7.  Diagnostic value of history taking in reflex syncope.

Authors:  N Colman; K Nahm; J G van Dijk; J B Reitsma; W Wieling; H Kaufmann
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

Review 8.  Non-invasive management of vasovagal syncope.

Authors:  Samuel T Coffin; Satish R Raj
Journal:  Auton Neurosci       Date:  2014-06-21       Impact factor: 3.145

Review 9.  Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypotension.

Authors:  Satish R Raj; Samuel T Coffin
Journal:  Prog Cardiovasc Dis       Date:  2013 Jan-Feb       Impact factor: 8.194

10.  Head-up tilt test: a highly sensitive, specific test for children with unexplained syncope.

Authors:  D Alehan; A Celiker; S Ozme
Journal:  Pediatr Cardiol       Date:  1996 Mar-Apr       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.